Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
1. Analysts expect BIIB to report earnings of $3.36 per share, up from $2.95. 2. Projected revenue for BIIB is $2.42 billion, slightly higher than last year. 3. Sage Therapeutics rejected BIIB's $7.22 per share proposal for strategic alternatives. 4. BIIB shares fell 2.2% to $139.39 ahead of earnings release. 5. Analysts recently downgraded BIIB's price targets, indicating cautious sentiment.